Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Yamshon

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Transplantation and Cellular Therapy|February 4, 2023
Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell TransplantationMohammad Alhomoud, Nora Chokr, Alexandra Gomez-Arteaga, et al.
Transplantation and Cellular Therapy|June 17, 2026
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysisNeela Easton, Mia Andreoli, Herman van Besien, et al.
JAMA Oncology|June 18, 2026
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-AnalysisJaromir Tomasik, Tobias Tix, Mohammad Alhomoud, et al.
Haematologica|July 10, 2025
Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysisMohammad Alhomoud, Rahma Ibrahim, Michelle Demetres, et al.
American Journal of Hematology|August 11, 2025
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR AnalysisJordan Gauthier, Kwang W Ahn, Jinalben Patel, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.
Blood Advances|March 19, 2026
Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin LymphomaGrace Baek, Gaurav Varma, Samuel Yamshon, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Transplantation and Cellular Therapy|February 4, 2023
Screening Chest CT Prior to Allogenic Hematopoietic Stem Cell TransplantationMohammad Alhomoud, Nora Chokr, Alexandra Gomez-Arteaga, et al.
Transplantation and Cellular Therapy|June 17, 2026
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysisNeela Easton, Mia Andreoli, Herman van Besien, et al.
JAMA Oncology|June 18, 2026
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-AnalysisJaromir Tomasik, Tobias Tix, Mohammad Alhomoud, et al.
Haematologica|July 10, 2025
Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysisMohammad Alhomoud, Rahma Ibrahim, Michelle Demetres, et al.
American Journal of Hematology|August 11, 2025
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR AnalysisJordan Gauthier, Kwang W Ahn, Jinalben Patel, et al.
Cancer Cell|December 6, 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionYusuke Isshiki, Xi Chen, Matt Teater, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.
Blood Advances|March 19, 2026
Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin LymphomaGrace Baek, Gaurav Varma, Samuel Yamshon, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Pageof 4